DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Average Recommendation of “Moderate Buy” from Brokerages

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) has been assigned a consensus rating of “Moderate Buy” from the six analysts that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $12.3333.

A number of equities analysts have weighed in on DMAC shares. Wall Street Zen upgraded DiaMedica Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research report on Monday, April 20th.

DiaMedica Therapeutics Price Performance

NASDAQ:DMAC traded up $0.03 during trading hours on Tuesday, hitting $8.04. The stock had a trading volume of 79,426 shares, compared to its average volume of 208,326. The company has a 50 day simple moving average of $6.16 and a two-hundred day simple moving average of $7.16. The firm has a market capitalization of $433.41 million, a price-to-earnings ratio of -11.38 and a beta of 0.97. DiaMedica Therapeutics has a one year low of $3.58 and a one year high of $10.42.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.02). Equities research analysts anticipate that DiaMedica Therapeutics will post -0.86 earnings per share for the current year.

Hedge Funds Weigh In On DiaMedica Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE increased its holdings in shares of DiaMedica Therapeutics by 62.5% in the 1st quarter. Bank of America Corp DE now owns 42,768 shares of the company’s stock worth $290,000 after buying an additional 16,446 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in shares of DiaMedica Therapeutics during the 1st quarter valued at $356,000. Sei Investments Co. lifted its holdings in shares of DiaMedica Therapeutics by 100.0% during the 1st quarter. Sei Investments Co. now owns 111,320 shares of the company’s stock worth $754,000 after acquiring an additional 55,660 shares during the last quarter. World Investment Advisors grew its position in DiaMedica Therapeutics by 7.7% in the fourth quarter. World Investment Advisors now owns 36,975 shares of the company’s stock worth $294,000 after acquiring an additional 2,650 shares in the last quarter. Finally, Invesco Ltd. grew its position in DiaMedica Therapeutics by 29.9% in the fourth quarter. Invesco Ltd. now owns 18,628 shares of the company’s stock worth $148,000 after acquiring an additional 4,293 shares in the last quarter. Hedge funds and other institutional investors own 10.12% of the company’s stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.